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Background: Renin-angiotensin-aldosterone (RAS) blockade has been demonstrated to have favorable effects in atherosclerosis. microRNA’s (miR) 
may affect multiple pathways relevant to atherosclerosis including those regulated by RAS pathways. We postulated that complete RAS blockade 
may result in differential regulation of miR’s that may be informative of renin-sensitive pathways and examined monocyte miR expression before and 
following treatment with aliskiren as part of a prospective trial.
methods: This was a single-center, randomized, double-blind, placebo-controlled clinical trial (NCT01417104) in patients with established 
cardiovascular disease. Patients were randomized to placebo (n=37, age 64.5±8.9 years) or aliskiren 300 mg qd (n=34, age 63.9±11.5 years). At 
baseline and 12 weeks of treatment blood monocytes were collected for miR expression, while 3D-dark blood MRI assessment of atherosclerosis in 
the aorta was conducted at baseline and at study completion (19-36 weeks). miRNA expression arrays (Nanostring Technologies) were performed on 
monocyte mRNA. miR expression was normalized (global sum) and significantly changed (>1.5-fold, p<0.05) miRs were assessed for correlation with 
changes in atheroma volume in the trial.
results: Three down-regulated miRs (hsa-miR-106b-5p, -27a-3p, and -18b-5p) were identified in patients after aliskiren administration. These 
miRs did not change in control patients receiving placebo. Baseline miR expression correlated significantly with increased normalized total wall 
volume (thoracic and abdominal) in subjects taking aliskiren (miR-106b, R=0.62; miR-27a, R=0.63; miR-18b, R=0.77, p<0.05 for all 3). Correlation 
was maintained when examined in those patients on ACEI/ARB therapy at baseline.
conclusions: Selective down-regulation of hsa-miR-106b-5p, -27a-3p, and -18b-5p in patients on renin blockade may represent pathway-specific 
adaptations to complete inhibition of the RAS system. The significance of these findings needs to be determined.
